Harmony Biosciences is trading at $37.17 (up 4.4%) in pre-market, extending its recent upward trend as investors position ahead of the company’s Q2 2026 earnings report.
- Analysts are expecting approximately $249 million in revenue and $0.97 EPS, with a sharp focus on WAKIX net product revenue performance.
- The stock continues to trade below the average analyst price target of $45.40, gaining momentum from its prior close of $35.60.